CRISPR is a family of genetic systems originally discovered as an adaptive defence mechanism in many bacteria and archaea, where CRISPR associated proteins use RNA guided recognition to identify and respond to genetic material from invading agents. The term derives from clustered regularly interspaced short palindromic repeats, referring to characteristic repeated DNA sequences separated by spacer sequences in microbial genomes. In biotechnology, CRISPR has become especially important because components of these natural systems can be adapted for programmable genetic manipulation.
A widely used system employs a CRISPR associated nuclease guided by RNA to recognise a complementary DNA sequence and modify it. CRISPR based technologies have therefore transformed experimental genetics by making targeted sequence recognition comparatively programmable, while also creating new approaches for gene regulation, diagnostics and genome engineering.
Natural CRISPR systems function as part of microbial adaptive immunity. During exposure to foreign genetic material, microorganisms can capture fragments of invading sequences and incorporate them as spacers within CRISPR arrays. These arrays are transcribed into RNA molecules that provide sequence information for later recognition. CRISPR associated proteins process or use these RNAs to identify complementary foreign nucleic acids and initiate their destruction or neutralisation. Different CRISPR systems use different proteins, guide RNA architectures and target molecules.
Type II systems containing Cas9 became especially influential in genome engineering because Cas9 can be directed by an RNA sequence to a complementary DNA target and can generate a double strand break under suitable conditions. The biotechnology field has subsequently expanded to many other CRISPR associated proteins with distinct molecular properties.
In widely used Cas9 based Gene Editing, a guide RNA directs Cas9 toward a DNA sequence through complementary base pairing. Cas9 also recognises a short adjacent DNA motif known as the protospacer adjacent motif, commonly abbreviated PAM, which contributes to target recognition. The requirement for an appropriate PAM means that not every DNA sequence is equally accessible to every Cas protein. Once correctly positioned, Cas9 can cut the DNA strands at a defined location relative to the guide and PAM. The cellular repair response then determines the final genetic outcome. If repair introduces small insertions or deletions, gene function can be disrupted. If a suitable repair template is available and the relevant repair pathway operates efficiently, more precise sequence changes can sometimes be introduced.
CRISPR technologies have expanded beyond conventional Cas9 mediated double strand breaks. Catalytically altered Cas proteins can be designed to bind DNA without cutting both strands, enabling transcriptional repression or activation when fused to appropriate regulatory domains. Base editors combine programmable targeting with enzymatic activities that can convert particular bases without requiring a conventional double strand break, although their editing windows and possible unintended changes impose constraints.
Prime editing uses a modified CRISPR associated protein and a specialised guide architecture to support certain sequence substitutions, insertions or deletions without relying on the same mechanism as conventional homology directed repair. Other CRISPR associated proteins target RNA rather than DNA and have applications in molecular detection and RNA manipulation. The term CRISPR therefore encompasses a rapidly expanding technological family rather than one single editing method.
CRISPR specificity depends on guide sequence, target sequence, PAM compatibility, chromatin context and molecular properties of the selected CRISPR associated protein. Unintended editing can occur at sequences that resemble the intended target, although the extent and distribution of such activity vary greatly among systems and experimental conditions. Improving specificity has involved engineering proteins, modifying guide designs, controlling exposure time and developing computational and experimental approaches for target assessment.
Another challenge is that editing can produce heterogeneous outcomes even at the intended locus. Some cells may remain unedited, others may acquire different sequence changes and some may contain larger genomic alterations. Reliable CRISPR research therefore requires careful controls and molecular characterisation rather than assuming that the programmed guide produces one uniform genetic outcome.
Delivery is a major determinant of CRISPR performance. The CRISPR components must reach the relevant cells at an effective concentration and, for genome editing, gain access to genomic DNA. Delivery methods vary according to organism, tissue, cell type and experimental objective. Viral vectors can provide efficient delivery to some cells but have constraints related to cargo capacity and biological interactions.
Nonviral approaches include lipid based particles and other molecular delivery systems, while laboratory experiments can use direct introduction into cultured cells or embryos. The choice between delivering DNA encoding CRISPR components, RNA molecules or preassembled protein RNA complexes can influence duration of activity and the resulting risk profile. Delivery is therefore inseparable from the practical performance of CRISPR based technologies.
CRISPR has become important in research because it can alter or regulate genes comparatively rapidly compared with many earlier targeted technologies. Researchers use CRISPR systems to create loss of function models, investigate gene regulatory networks, perform pooled genetic screens and examine interactions among genes. CRISPR based screening can introduce large numbers of guide RNAs into cell populations so that particular genes can be perturbed and associated phenotypes measured.
CRISPR associated proteins can also be used for molecular diagnostics by exploiting sequence specific recognition and signal generation. In agriculture, CRISPR can be used experimentally to investigate or alter traits in crops and animals. In medicine, CRISPR based approaches are being investigated for treating genetic diseases and modifying cells, with clinical use requiring extensive validation and regulatory oversight.
CRISPR is frequently confused with Gene Editing, but the terms have different scopes. Gene Editing describes the broader activity of deliberately altering genetic sequences, whereas CRISPR identifies a family of naturally derived molecular systems and the technologies built from them. Not every CRISPR application edits DNA. Some CRISPR systems regulate gene expression, target RNA or detect nucleic acids without permanently changing the genome. Similarly, not all Gene Editing uses CRISPR because earlier and alternative systems can perform targeted genetic modification. CRISPR should also not be described as perfectly precise simply because its targeting is programmable. Specificity, editing efficiency, cellular repair, delivery and genomic context all affect outcomes.
